An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
暂无分享,去创建一个
T. Salame | Y. Yarden | J. Downward | H. Gal | V. Krizhanovsky | Maicol Mancini | Yehoshua Enuka | Ilaria Marrocco | A. Maraver | E. Bousquet | D. Burton | L. Roth | N. Gaborit | M. Lindzen | Donatella Romaniello | G. Mahlknecht | Ashish Noronha | L. Mazzeo | Dan Adreka | Raya Eilam Altstadter | D. Romaniello | Moshit Lindzen | Emilie Bousquet | Hilah Gal | Luigi Mazzeo
[1] D. Bell,et al. EGFR mutation , 2019, Radiopaedia.org.
[2] Chia-Chi Lin,et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Ahn,et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.
[4] T. T. Poulsen,et al. Pan‐HER—An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand‐induced EGFR homo‐ and heterodimers , 2016, International journal of cancer.
[5] Yosef Yarden,et al. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18 , 2016, British journal of pharmacology.
[6] Y. Yarden,et al. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3 , 2016, Human vaccines & immunotherapeutics.
[7] Bruce A. Posner,et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells , 2016, Nature Communications.
[8] Y. Yarden,et al. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. , 2016, Seminars in cell & developmental biology.
[9] G. Getz,et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.
[10] D. Planchard,et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] W. Pao,et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. , 2015, Cancer research.
[12] Y. Yarden,et al. Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer , 2015, Science Signaling.
[13] P. Jänne,et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.
[14] J. Yang,et al. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer , 2015, Current opinion in oncology.
[15] S. Kobayashi,et al. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. , 2015, Translational lung cancer research.
[16] H. Groen,et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. , 2014, Cancer discovery.
[17] W. Pao,et al. Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.
[18] V. Krizhanovsky,et al. Physiological and pathological consequences of cellular senescence , 2014, Cellular and Molecular Life Sciences.
[19] F. Bensch,et al. Associate editor: B. TeicherHER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting , 2014 .
[20] Manuel Serrano,et al. Cellular senescence: from physiology to pathology , 2014, Nature Reviews Molecular Cell Biology.
[21] Peilin Jia,et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. , 2014, Cell reports.
[22] R. Bernards,et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. , 2014, Cancer discovery.
[23] G. Keating. Afatinib: A Review of Its Use in the Treatment of Advanced Non-Small Cell Lung Cancer , 2014, Drugs.
[24] M. Narita,et al. Cellular senescence and its effector programs , 2014, Genes & development.
[25] V. Krizhanovsky,et al. Immunosurveillance of senescent cells: the bright side of the senescence program , 2013, Biogerontology.
[26] S. Lowe,et al. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells , 2013, The Journal of experimental medicine.
[27] C. Foy,et al. Evaluation of Digital PCR for Absolute RNA Quantification , 2013, PloS one.
[28] J. Fischer,et al. Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation , 2013, Science Translational Medicine.
[29] S. Mamidi,et al. Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab , 2013, Molecular oncology.
[30] Darjus F. Tschaharganeh,et al. Non-Cell-Autonomous Tumor Suppression by p53 , 2013, Cell.
[31] J. Campisi. SENESCENCE RESPONSE TO OXIDATIVE & GENOTOXIC STRESS: A LINK BETWEEN AGING AND DISEASE , 2012 .
[32] M. Serrano. Cancer: Final act of senescence , 2011, Nature.
[33] M. Ladanyi,et al. New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer , 2011, Clinical Cancer Research.
[34] R. Plummer,et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] John R. Engen,et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.
[36] W. Pao,et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. , 2009, The Journal of clinical investigation.
[37] J. Abbruzzese,et al. F1000 highlights , 2009, JAMA.
[38] M. Ychou,et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] F. D. D. Fagagna. Living on a break: cellular senescence as a DNA-damage response , 2008, Nature Reviews Cancer.
[40] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] W. Pao,et al. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.
[42] S. Groshen,et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[44] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[45] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[46] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[47] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[48] Daniel Jones. Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.
[49] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[50] L. Sequist,et al. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[51] Benjamin G. Gowen,et al. Recognition of tumors by the innate immune system and natural killer cells. , 2014, Advances in immunology.
[52] S. Lowe,et al. p 53-dependent chemokine production by senescent tumor cells supports NKG 2 D-dependent tumor elimination by natural killer cells , 2013 .
[53] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[54] the original work is properly cited. , 2022 .